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81 Susceptibility of Exophiala dermatitidis to antifungal agents
N. Kondori1, C. Welinder-Olsson1. 1Sahlgrenska University Hospital, Clinical
Microbiology, Gothenburg, Sweden
Objectives: Patients with cystic ﬁbrosis (CF) are at constant risk for pulmonary
colonization by opportunistic microorganisms. The black yeast, Exophiala dermati-
tidis, has consistently been isolated from patients with CF. The aim of this study
was to determine the minimal inhibitory concentrations (MIC) for itraconazole,
voriconazole, posaconazole, ﬂucytosine and amphoterricin against E. dermatitidis.
Methods: Since E. dermatitidis grows initially in the yeast form and acquires mould
form with age, two methods i.e. the Clinical and laboratory Standards Institute
(CLSI) for moulds and the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) for yeasts have been used. The results obtained from the two
analytical systems were compared.
Results: The overall agreement between CLSI and EUCAST was good (>90%),
with the exception for posaconazole and ﬂucytosine.
Conclusion: The antifungal susceptibility testing of 53 clinical isolates, using
CLSI and EUCAST shows that posaconazole was the most active drug against
E. dermatitidis in vitro followed by voriconazole and itraconazole in both systems.
82 Effect of ivacaftor on CF clinical isolates of Pseudomonas
aeruginosa, Staphylococcus aureus and Streptococcus sp. in
comparison to antimicrobial peptides
J. Payne1,2, D. McLean1, L. McIlreavey1, S.J. McGrath1, M. Tunney1, S. Weldon2,
C. Taggart2, J.S. Elborn1. 1Queen’s University Belfast, CF & Airways Microbiology
Research Group, Belfast, United Kingdom; 2Queen’s University Belfast, Centre for
Infection and Immunity, Belfast, United Kingdom
Objectives: It has been suggested that, as there is a quinolone ring in the structure of
ivacaftor, it may have some antimicrobial activity against CF pathogens. Therefore,
the aims of this study were to (1) determine whether ivacaftor demonstrates any
antimicrobial activity against CF clinical isolates, and (2) compare the activity of
ivacaftor to a standard panel of antibiotics used in CF therapy and human antimicrobial
peptides (AMPs) which are naturally produced as part of the innate immune response.
Methods: The minimum inhibitory concentration (MIC) ivacaftor, Colistin, and a range
of AMPs against clinical isolates from CF patients (P. aeruginosa, Streptococcus sp.
and S. aureus) were determined using radial diffusion assays. Antibiotic susceptibility
was determined by Etest®.
Results: See the table. At the concentrations tested ivacaftor had no direct antimicrobial
activity against any of the clinical isolates tested. Human b-defensin 3 was the most
effective AMP against the Gram positive isolates tested.
Table: MICs of ivacaftor, AMPs and antibiotics
MIC (mg/ml)
P. aeruginosa Streptococcus sp. S. aureus
Ivacaftor >50 >50 >50
Lysozyme 19.5–57.2 − >250
b-defensin 3 − 1.38–21.78 5.65–47.5
Colistin 1.5−7.7 1−1.3 >10
Tobramycin 0.38−8 0.094−>256 0.094−34
Meropenem 0.016−12 0.016–0.75 0.125−>32
Ciproﬂoxacin 0.064−4 0.38−1.5 0.19−>32
Conclusion: Ivacaftor does not have any direct antimicrobial activity against the clinical
isolates tested. The MIC values for the AMPs tested varied between and within the
different genera tested, suggesting that isolates possess a range of virulence factors
which affect AMP activity.
Work supported by a DEL NI studentship, CFMATTERS (EU FP7) and a US–Ireland
Project Partnership Grant.
83 Bronchopulmonary infection/colonization in cystic ﬁbrosis: results
from a Spanish multicenter study
J.D.D. Caballero1,2, M. Cobo1,2, G. Chincho´n1, C. Lo´pez-Causape´3, A. Oliver3,
E. Go´mez de la Pedrosa1,2, R. del Campo1,2, M. Tato1,2, R. Canto´n1,2, GEIFQ (Grupo
Espan˜ol para el Estudio de la Colonizacio´n/Infeccio´n Broncopulmonar en Fibrosis
Quı´stica). 1Hospital Universitario Ramo´n y Cajal, Microbiology and Parasitology,
Madrid, Spain; 2Instituto Ramo´n y Cajal de Investigacio´n Sanitaria (IRYCIS)),
Madrid, Spain; 3Hospital Universitari Son Espases, Microbiology and Parasitology,
Palma de Mallorca, Spain
Objectives: To identify and characterize the lung microbiota of Spanish cystic ﬁbrosis
(CF) patients from a national multicenter study (March-November, 2013) focusing in
the major pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus.
Methods: 13 adult and 11 paediatric CF-Units from 17 Hospitals covering different
areas in Spain participated in the study. Each one collected respiratory samples and
clinical data of 15 non-selected consecutive patients. Samples were immediately stored
(−80ºC) and sent to our hospital for quantitative culture, identiﬁcation (MALDI-TOF
MS) and antibiotic susceptibility (MicroScan).
Results: 340 patients were included, 177 adults (52.1%) and 163 children (47.9%),
median age of 24.5 and 10 years, respectively. 33.9% of patients were homozygous for
F508del and 46.4% were heterozygous. Pulmonary function had a mean (SD) FVE1 of
59.1% (34.0) and 69.5% (30.2) for adults and children, respectively. P. aeruginosa was
isolated in 49 (27.7%) adult and 25 (15.3%) paediatric patients. Other CF pathogens
isolated are in the table below. Co-colonization was a frequent event.
Conclusion: S. aureus was the most frequent CF pathogen, followed by P. aeruginosa
and other non-fermenting Gram-negative rods (NFGNR). P. aeruginosa colonization
was lower than expected, especially in the adult subset. This could reﬂect an improve-
ment in the clinical and therapeutic approach to CF and a positive impact of the neonatal
screening.
Frequency of colonization (%)
Total Adults Children
S. aureus 59.7 57.6 62.0
P. aeruginosa 21.8 27.7 15.3
NFGNR 25.6 25.9 25.2
84 Respiratory microbiota in children with cystic ﬁbrosis and healthy
controls
C.W. Holmes1, D.W. Rivett2, D.E. Modha1, K.D. Bruce2, E.A. Gaillard3.
1University Hospitals Leicester, Clinical Microbiology, Leicester, United Kingdom;
2King’s College London, Institute of Pharmaceutical Science, London, United
Kingdom; 3University of Leicester, Department of Infection, Immunity and
Inﬂammation, Leicester, United Kingdom
Background: The CF respiratory microbiome contains diverse bacterial species
that are not routinely cultured. Few studies have examined airways microbiota in
young children with CF from whom sputum samples are difﬁcult to obtain. Studies
such as these are important to understand the changes in airway microbiota over
time and how this affects long term respiratory health in CF.
Aims: To characterise the airways microbiota of young children with CF and
compare microbial diversity with older CF and healthy children.
Methods: Sputum and BAL samples were collected from children with CF respira-
tory exacerbations and healthy controls. Bacterial density was quantiﬁed by a real-
time PCR assay targeting the 16S rRNA gene and identiﬁed by 454-pyrosequencing
of a fragment of the same gene, with these data assessed for richness, diversity and
equability.
Results: Microbiome sequencing revealed that diversity and richness were highest
in control patients. In CF patients there was a correlation between patient age
and declining diversity although these trends were not statistically signiﬁcant.
Diversity was lowest in samples containing known pathogens from genera such as
Staphylococcus, Achromobacter, Pseudomonas and Stenotrophomonas. We found
no signiﬁcant differences in microbiota richness or diversity between BAL and
sputum samples from young children.
Conclusions: These data highlight the complicated bacterial population structures
within the airways of young children and changes occurring over time in CF patients.
A more complete understanding of the dynamics of these populations will be
beneﬁcial in improving the management of respiratory infection in CF.
